Vyant Bio (NASDAQ:VYNT) Inc CEO Jay Roberts and chief scientific officer Robert Fremeau tells Proactive it has entered into a collaboration agreement with OrganoTherapeutics to accelerate the discovery of drugs to treat Parkinson's Disease. The collaboration brings together the companies' expertise in drug discovery using human-derived cells, high-throughput biology and chemistry, and machine learning-based therapeutic design to identify potential drugs to treat PD.
Vyant Bio enters collaboration with Organo Therapeutics to find treatments for Parkinson's Disease
